These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 21692620)

  • 21. Opening of the national biobank of Korea as the infrastructure of future biomedical science in Korea.
    Cho SY; Hong EJ; Nam JM; Han B; Chu C; Park O
    Osong Public Health Res Perspect; 2012 Sep; 3(3):177-84. PubMed ID: 24159511
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single-cell RNA sequencing of a European and an African lymphoblastoid cell line.
    Osorio D; Yu X; Yu P; Serpedin E; Cai JJ
    Sci Data; 2019 Jul; 6(1):112. PubMed ID: 31273215
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EBV transformation overrides gene expression patterns of B cell differentiation stages.
    Siemer D; Kurth J; Lang S; Lehnerdt G; Stanelle J; Küppers R
    Mol Immunol; 2008 Jun; 45(11):3133-41. PubMed ID: 18430472
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacogenomics of chemotherapeutic susceptibility and toxicity.
    Moen EL; Godley LA; Zhang W; Dolan ME
    Genome Med; 2012; 4(11):90. PubMed ID: 23199206
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chromosomal variation in lymphoblastoid cell lines.
    Shirley MD; Baugher JD; Stevens EL; Tang Z; Gerry N; Beiswanger CM; Berlin DS; Pevsner J
    Hum Mutat; 2012 Jul; 33(7):1075-86. PubMed ID: 22374857
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nordic biological specimen bank cohorts as basis for studies of cancer causes and control: quality control tools for study cohorts with more than two million sample donors and 130,000 prospective cancers.
    Pukkala E
    Methods Mol Biol; 2011; 675():61-112. PubMed ID: 20949384
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DNA damage-associated dysregulation of the cell cycle and apoptosis control in cells with germ-line p53 mutation.
    Goi K; Takagi M; Iwata S; Delia D; Asada M; Donghi R; Tsunematsu Y; Nakazawa S; Yamamoto H; Yokota J; Tamura K; Saeki Y; Utsunomiya J; Takahashi T; Ueda R; Ishioka C; Eguchi M; Kamata N; Mizutani S
    Cancer Res; 1997 May; 57(10):1895-902. PubMed ID: 9157982
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel model for prognosis of Meniere's disease using oxidative stress susceptibility of lymphoblastoid cell lines.
    Hayashi K; Kobayashi R; Kitamura K; Goto F; Ogawa K; Matsumoto T
    Biosci Trends; 2010 Apr; 4(2):72-8. PubMed ID: 20448344
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dominant expansion of a cryptic subclone with an abnormal karyotype in B lymphoblastoid cell lines during culture.
    Danjoh I; Shirota R; Hiroyama T; Nakamura Y
    Cytogenet Genome Res; 2013; 139(2):88-96. PubMed ID: 23128794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HLA-restricted presentation of WT1 tumor antigen in B-lymphoblastoid cell lines established using a maxi-EBV system.
    Kanda T; Ochi T; Fujiwara H; Yasukawa M; Okamoto S; Mineno J; Kuzushima K; Tsurumi T
    Cancer Gene Ther; 2012 Aug; 19(8):566-71. PubMed ID: 22722376
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Integrating clinical information in National Biobank of Korea.
    Kim H; Yi BK; Kim IK; Kwak YS
    J Med Syst; 2011 Aug; 35(4):647-56. PubMed ID: 20703524
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human B-lymphoid cell lines.
    Nilsson K
    Hum Cell; 1992 Mar; 5(1):25-41. PubMed ID: 1329931
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential expression of nucleoskeleton- and cytoskeleton-associated proteins in Burkitt lymphoma-derived and Epstein-Barr virus-immortalized lymphoblastoid cell lines.
    Szekely L; Pokrovskaja K; Klein G
    Cell Growth Differ; 1997 May; 8(5):599-609. PubMed ID: 9149911
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The biobanking research infrastructure BBMRI_CZ: a critical tool to enhance translational cancer research.
    Holub P; Greplova K; Knoflickova D; Nenutil R; Valik D
    Klin Onkol; 2012; 25 Suppl 2():2S78-81. PubMed ID: 23581021
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extending the lymphoblastoid cell line model for drug combination pharmacogenomics.
    Green AJ; Anchang B; Akhtari FS; Reif DM; Motsinger-Reif A
    Pharmacogenomics; 2021 Jun; 22(9):543-551. PubMed ID: 34044623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Taiwan Biobank: a project aiming to aid Taiwan's transition into a biomedical island.
    Fan CT; Lin JC; Lee CH
    Pharmacogenomics; 2008 Feb; 9(2):235-46. PubMed ID: 18370851
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacogenomic Discovery Delineating the Genetic Basis of Drug Response.
    Zhang W; Zheng Y; Hou L
    Curr Genet Med Rep; 2013 Sep; 1(3):143-149. PubMed ID: 24015375
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Integrating Epigenomics into Pharmacogenomic Studies.
    Zhang W; Huang RS; Dolan ME
    Pharmgenomics Pers Med; 2008 Nov; 2008(1):7-14. PubMed ID: 20622972
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Baseline cell proliferation rates and response to UV differ in lymphoblastoid cell lines derived from healthy individuals of extreme constitution types.
    Chakraborty S; Singhmar S; Singh D; Maulik M; Patil R; Agrawal SK; Mishra A; Ghazi M; Vats A; Natarajan VT; Juvekar S; Prasher B; Mukerji M
    Cell Cycle; 2021 May; 20(9):903-913. PubMed ID: 33870855
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differences between the genomes of lymphoblastoid cell lines and blood-derived samples.
    Joesch-Cohen LM; Glusman G
    Adv Genomics Genet; 2017; 7():1-9. PubMed ID: 28736497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.